Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-057187
Filing Date
2026-05-07
Accepted
2026-05-07 16:25:43
Documents
62
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nxtc-20260331x10q.htm   iXBRL 10-Q 995836
2 EX-10.1 nxtc-20260331xex10d1.htm EX-10.1 62151
3 EX-31.1 nxtc-20260331xex31d1.htm EX-31.1 12850
4 EX-31.2 nxtc-20260331xex31d2.htm EX-31.2 12631
5 EX-32.1 nxtc-20260331xex32d1.htm EX-32.1 12269
6 GRAPHIC nxtc-20260331xex10d1001.jpg GRAPHIC 13036
  Complete submission text file 0001104659-26-057187.txt   5256449

Data Files

Seq Description Document Type Size
7 EX-101.SCH nxtc-20260331.xsd EX-101.SCH 38486
8 EX-101.CAL nxtc-20260331_cal.xml EX-101.CAL 41501
9 EX-101.DEF nxtc-20260331_def.xml EX-101.DEF 142510
10 EX-101.LAB nxtc-20260331_lab.xml EX-101.LAB 366419
11 EX-101.PRE nxtc-20260331_pre.xml EX-101.PRE 243002
66 EXTRACTED XBRL INSTANCE DOCUMENT nxtc-20260331x10q_htm.xml XML 853639
Mailing Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705
Business Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705 240-399-4900
NextCure, Inc. (Filer) CIK: 0001661059 (see all company filings)

EIN.: 475231247 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38905 | Film No.: 26953950
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)